Skip to main content
Top
Published in: Strahlentherapie und Onkologie 1/2016

01-01-2016 | Literatur kommentiert

Überlebensvorteil durch Kombination von Bevacizumab mit konventioneller Radiochemotherapie bei Glioblastomen vom proneuralen Subtyp?

Authors: Dr. Clemens Seidel, Prof. Dr. Rolf-Dieter Kortmann

Published in: Strahlentherapie und Onkologie | Issue 1/2016

Login to get access

Auszug

Glioblastome sind heterogene Erkrankungen. Neben der Unterteilung anhand einzelner (epi-)genetischer Charakteristika (u. a. MGMT-Promotorstatus, IDH1/2-Mutationsstatus) ist eine Unterteilung anhand von Genexpressionsprofilen in prognostisch relevante Subtypen (proneurale, klassisch proliferative, mesenchymale) möglich [13]. In den beiden großen Phase-III-Studien (AVAglio und RTOG-0825), welche die Wirksamkeit von BEV in der Erstlinientherapie bei Glioblastomen untersuchten, wurde weder für die Gesamtpopulation noch nach Unterteilung in MGMT-Promotor- bzw. IDH1/2-Mutationsstatus ein differentieller Effekt der Prüfsubstanz auf das Gesamtüberleben gezeigt [4, 5]. Dennoch entspricht es der klinischen Beobachtung, dass manche Patienten einen langfristigen Überlebensvorteil von BEV haben, wogegen viele nur kurzfristig durch antiödematöse Effekte oder gar nicht von BEV profitieren. …
Literature
1.
go back to reference Phillips HS, Kharbanda S, Chen RH et al (2006) Molecular subclasses of high-grade glioma predict prognosis delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173PubMedCrossRef Phillips HS, Kharbanda S, Chen RH et al (2006) Molecular subclasses of high-grade glioma predict prognosis delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173PubMedCrossRef
3.
go back to reference Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110PubMedPubMedCentralCrossRef Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110PubMedPubMedCentralCrossRef
4.
go back to reference Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722PubMedCrossRef Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722PubMedCrossRef
5.
6.
go back to reference Sulman EP, Won M, Blumenthal DT et al (2013) Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 31:116s. (suppl 15s; abstr LBA2010) Sulman EP, Won M, Blumenthal DT et al (2013) Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). J Clin Oncol 31:116s. (suppl 15s; abstr LBA2010)
7.
go back to reference Bais C, Rabe C, Wild N et al (2014) Comprehensive re-assessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in thirteen pivotal trials (seven indications). J Clin Oncol 32:189s. (suppl 15s; abstr 3040) Bais C, Rabe C, Wild N et al (2014) Comprehensive re-assessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in thirteen pivotal trials (seven indications). J Clin Oncol 32:189s. (suppl 15s; abstr 3040)
8.
go back to reference Lambrechts D, Lenz HJ, de Haas S et al (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219–1230PubMedCrossRef Lambrechts D, Lenz HJ, de Haas S et al (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219–1230PubMedCrossRef
9.
go back to reference Jubb AM, Hurwitz HI, Bai W et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer. J Clin Oncol 24:217–227PubMedCrossRef Jubb AM, Hurwitz HI, Bai W et al (2006) Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizurnab in metastatic colorectal cancer. J Clin Oncol 24:217–227PubMedCrossRef
10.
go back to reference Brauer MJ, Zhuang GL, Schmidt M et al (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19:3681–3692PubMedCrossRef Brauer MJ, Zhuang GL, Schmidt M et al (2013) Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 19:3681–3692PubMedCrossRef
Metadata
Title
Überlebensvorteil durch Kombination von Bevacizumab mit konventioneller Radiochemotherapie bei Glioblastomen vom proneuralen Subtyp?
Authors
Dr. Clemens Seidel
Prof. Dr. Rolf-Dieter Kortmann
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 1/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0922-3

Other articles of this Issue 1/2016

Strahlentherapie und Onkologie 1/2016 Go to the issue